AKTIONÄR-Depotwert Vitrolife: Wilder Ritt nach de Zahlen – the Details

The Scandinavian Reproduktionsmedizin-Spezialist Vitrolife hat am Donnerstag with the Zahlen zum dririjders Quartal that Marktwartungen lightly painted. As you can imagine, this is a problem and trading volatility is out of the question.

Zum Handelsstart an der Heimatbörse in Stockholm nodded der Wert zunächst um bis zu zehn Prozent ein. The Tages entry is from the AKTIONÄR-Depot that in this en schloss sogar with 2.3 Prozent in Plus.

Vitrolife reported a turnover increase of 867 million Swedish kroner (75.8 million euros), analysts had estimated 899 million kroner. The result is that the Gesellschaft ein Ergebnis je Aktie in Höhe von 0.85 Kronen after 0.90 Kronen in Vorjahreszeitraum. The estimate was hinged at 1.01 Kronen Gewinn pro Papier.

In an initial response, DNB analyst Patrik Ling described the quarters as “soft”. Experts say that they are a “few ermutating Anzeichen”, which contains the organic Wachstum von If you want to conduct a research in the history of the history and community of the Genetic Service in North America, it has become one of the results.

The reported Q3 warnings lie about a pleasure The results of the analyzes become higher than the errors, so the analysis of Redeye’s analysts. Vitrolife is now on the best track, with a Wachstumsrate there is, which no longer lies an elongated Soul of über zehn Prozent, so the experts in a Research Update.